Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | GDC-0980 | 3 | 72 | 3.2 | 432.8 | 3324.8 | 586.9 | 0.505 | -0.115 | 0.130 | 2.502 | BT20 GDC0980 0 3 |
| BT-20 | GDC-0980 | 3 | 72 | 1.0 | 578.3 | 3324.8 | 586.9 | 0.0 | -0.006 | 0.174 | 2.502 | BT20 GDC0980 0 3 |
| BT-20 | GDC-0980 | 3 | 72 | 0.32 | 807.5 | 3324.8 | 586.9 | -0.495 | 0.136 | 0.243 | 2.502 | BT20 GDC0980 0 3 |
| BT-20 | GDC-0980 | 3 | 72 | 0.1 | 1475.0 | 3324.8 | 586.9 | -1.0 | 0.445 | 0.444 | 2.502 | BT20 GDC0980 0 3 |
| BT-20 | GDC-0980 | 3 | 72 | 0.032 | 2882.3 | 3324.8 | 586.9 | -1.49 | 0.889 | 0.867 | 2.502 | BT20 GDC0980 0 3 |
| BT-20 | GDC-0980 | 3 | 72 | 0.01 | 3349.8 | 3324.8 | 586.9 | -2.0 | 1.010 | 1.010 | 2.502 | BT20 GDC0980 0 3 |
| BT-20 | GDC-0980 | 3 | 72 | 0.0032 | 3421.5 | 3324.8 | 586.9 | -2.49 | 1.020 | 1.030 | 2.502 | BT20 GDC0980 0 3 |
| BT-20 | GDC-0980 | 3 | 72 | 0.001 | 3400.5 | 3324.8 | 586.9 | -3.0 | 1.020 | 1.020 | 2.502 | BT20 GDC0980 0 3 |
| BT-20 | Pictilisib | 3 | 72 | 3.2 | 881.8 | 3476.3 | 586.9 | 0.505 | 0.172 | 0.254 | 2.566 | BT20 GDC0941 0 3 |
| BT-20 | Pictilisib | 3 | 72 | 1.0 | 1461.3 | 3476.3 | 586.9 | 0.0 | 0.427 | 0.420 | 2.566 | BT20 GDC0941 0 3 |
| BT-20 | Pictilisib | 3 | 72 | 0.32 | 2592.0 | 3476.3 | 586.9 | -0.495 | 0.784 | 0.746 | 2.566 | BT20 GDC0941 0 3 |
| BT-20 | Pictilisib | 3 | 72 | 0.1 | 3007.0 | 3476.3 | 586.9 | -1.0 | 0.890 | 0.865 | 2.566 | BT20 GDC0941 0 3 |
| BT-20 | Pictilisib | 3 | 72 | 0.032 | 3393.0 | 3476.3 | 586.9 | -1.49 | 0.981 | 0.976 | 2.566 | BT20 GDC0941 0 3 |
| BT-20 | Pictilisib | 3 | 72 | 0.01 | 3237.5 | 3476.3 | 586.9 | -2.0 | 0.945 | 0.931 | 2.566 | BT20 GDC0941 0 3 |
| BT-20 | Pictilisib | 3 | 72 | 0.0032 | 3100.0 | 3476.3 | 586.9 | -2.49 | 0.913 | 0.892 | 2.566 | BT20 GDC0941 0 3 |
| BT-20 | Pictilisib | 3 | 72 | 0.001 | 2951.5 | 3476.3 | 586.9 | -3.0 | 0.876 | 0.849 | 2.566 | BT20 GDC0941 0 3 |
| BT-20 | Everolimus | 3 | 72 | 3.2 | 1503.5 | 3144.8 | 586.9 | 0.505 | 0.475 | 0.478 | 2.422 | BT20 Everolimus 0 3 |
| BT-20 | Everolimus | 3 | 72 | 1.0 | 1644.5 | 3144.8 | 586.9 | 0.0 | 0.530 | 0.523 | 2.422 | BT20 Everolimus 0 3 |
| BT-20 | Everolimus | 3 | 72 | 0.32 | 1689.0 | 3144.8 | 586.9 | -0.495 | 0.547 | 0.537 | 2.422 | BT20 Everolimus 0 3 |
| BT-20 | Everolimus | 3 | 72 | 0.1 | 1720.0 | 3144.8 | 586.9 | -1.0 | 0.559 | 0.547 | 2.422 | BT20 Everolimus 0 3 |
| BT-20 | Everolimus | 3 | 72 | 0.032 | 1627.3 | 3144.8 | 586.9 | -1.49 | 0.524 | 0.517 | 2.422 | BT20 Everolimus 0 3 |
| BT-20 | Everolimus | 3 | 72 | 0.01 | 1652.8 | 3144.8 | 586.9 | -2.0 | 0.533 | 0.526 | 2.422 | BT20 Everolimus 0 3 |
| BT-20 | Everolimus | 3 | 72 | 0.0032 | 1762.8 | 3144.8 | 586.9 | -2.49 | 0.575 | 0.561 | 2.422 | BT20 Everolimus 0 3 |
| BT-20 | Everolimus | 3 | 72 | 0.001 | 1827.0 | 3144.8 | 586.9 | -3.0 | 0.598 | 0.581 | 2.422 | BT20 Everolimus 0 3 |
| BT-20 | CAL-101 | 3 | 72 | 3.2 | 3158.8 | 3531.5 | 586.9 | 0.505 | 0.916 | 0.894 | 2.589 | BT20 CAL101 0 3 |